Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > REGULATORY
REGULATORY
- Japan Mulls Moving Up Omicron Boosters to September
August 31, 2022
- University of Tokyo Selected as Flagship R&D Site to Orchestrate Japan’s Vaccine Efforts: SCARDA Project
August 31, 2022
- Japan Approves AstraZeneca’s COVID-19 Cocktail Therapy Evusheld
August 30, 2022
- Pfizer’s COVID Booster Approved for Children Aged 5-11 in Japan
August 30, 2022
- LDP Group Eyes Proposal on Generic Distribution, Pricing; Expert Wants Penalty on Healthcare Providers Getting Undue Discounts
August 30, 2022
- AZ’s Asthma Drug Tezepelumab Clears MHLW Panel Review; BMS’ Psoriasis Med, MSD/Sanofi Jabs Too
August 30, 2022
- AstraZeneca’s COVID Cocktail in Line for Approval, Comirnaty Booster for Ages 5-11
August 30, 2022
- Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
- MHLW’s Health Service Bureau to Seek Funding for “Income Security System” for Antimicrobials for FY2023
August 29, 2022
- MHLW’s Health Policy Bureau to Seek Budget for Research into Integrating Drug Supply Info, Clarification of Generic Ratio
August 29, 2022
- MHLW Begins Discussions on Potential Use of Non-Doctor/Nurse Healthcare Professionals as Vaccinators
August 29, 2022
- MHLW’s Pharma Bureau to Request Budget to Promote RWD Use in Regulatory Filing for FY2023
August 26, 2022
- MHLW to Seek 400 Million Yen for AI-Powered Drug Discovery for Cancer: FY2023 Budget Request
August 26, 2022
- MHLW Seeks 2-Year Extension of Raise on R&D Tax Credit Ceiling: FY2023 Reform Request
August 26, 2022
- MHLW’s Health Policy Bureau Eyes COI Management System, Upgraded Clinical Research Database: FY2023 Budget Request
August 26, 2022
- MHLW to Request a 33.26 Trillion Yen General Account Budget for FY2023
August 26, 2022
- Lilly’s Tirzepatide in Line for Approval as Early as September as Japan’s 1st GIP/GLP-1 Agent
August 26, 2022
- Japan Approves Label Expansions for Lynparza, Ultomiris, Keytruda, Tagrisso, and More
August 25, 2022
- 1st Meeting of New Drug Distribution and Pricing Panel Set for Aug. 31
August 25, 2022
- AstraZeneca’s COVID Cocktail Up for Aug. 29 PAFSC Session; Comirnaty Pediatric Booster Too
August 23, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…